Stock Analysis:Becton Dickinson and Co (NYSE:BDX) Stock Target Has Just Been Increased
In an interesting research report sent to investors and clients by Raymond James on 11 December, Becton Dickinson and Co (NYSE:BDX) had its target price increased to $176.00. The firm now has a solid Strong Buy rating on shares.
From a total of 16 analysts covering Becton Dickinson (NYSE:BDX) stock, 12 rate it a ”Buy”, 0 a “Sell”, and 6 a ”Hold”. This means that 67% of the ratings are positive. The highest target price is $175 while the lowest target price is $153. The mean of all analyst targets is $165.13 with a 5.00% above today’s ($152.19) stock price. Becton Dickinson was the topic of 5 analyst reports since August 7, 2015 according to the firm StockzIntelligence Inc. Citigroup initiated shares on November 12 with “Neutral” rating. Deutsche Bank maintained BDX stock in a recent report from August 10 with “Hold” rating.
Approximately 482,436 shares of stock traded hands. Becton Dickinson and Co (NYSE:BDX) has risen 8.69% since May 8, 2015 and is uptrending. It has outperformed by 11.71% the S&P500.
The overall sentiment of institutions has increased to 1.03 in Q2 2015. Its up 0.19, from 0.84 in 2015Q2. The ratio is positive, as 43 institutions have sold all the shares of Becton Dickinson and Co that they owned while 315 funds have taken shares off the table. 59 funds have purchased shares for the first time while 310 added to their positions. These institutions now hold 187.34 million shares or 8.81% more than the 172.16 million shares they owned in 2015Q2.
The Fund Fundsmith Llp currently is holding shares equating to 6.4% of its total portfolio in Becton Dickinson and Co representing a total of 1.58 million shares. Another fund,Jensen Investment Management Inc, is holding a total of 2.37 million shares equating to 5.54% of their holdings. Additionally, Caledonia Investments Plc has a 110,800 share stake in Becton Dickinson and Co which represents 5.29% of their total portfolio. The Fund, Endurant Capital Management Lp, based out of California, has also built up a stake in the stock, which represents a total of 4.76% of their total portfolio. Finally Sfe Investment Counsel, a fund which is based in the state of California reported a total holdings of 66,179 shares.
Becton, Dickinson and Company is a global medical technology firm engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry and the general public. The company has a market cap of $32.66 billion. The Firm operates through two divisions: BD Medical and BD Life Sciences. It has 44.77 P/E ratio. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences divisions.
According to Zacks Investment Research, “Becton, Dickinson and Co. is engaged principally in the manufacture and sale of a broad line of supplies, devices and systems used by health care professionals, medical research institutions and the general public. BD’s operations consist of three worldwide business segments: Medical Systems, Biosciences, and Preanalytical Solutions.” Get a free copy of the Zacks research report on Becton Dickinson and Co (BDX).